Paul Corn, MD
Medical Oncology · Houston, TXNPI 1629164314
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 39.4% of the total. 2025 is the largest year on record at $468, 5.5 times the $85 reported in 2020. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 41 payments — averaging $25.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$407
- Exelixis Inc.$393
- Janssen Scientific Affairs, LLC$127
- Sanofi-aventis U.S. LLC$68
- AstraZeneca$20
- Sumitomo Pharma America, Inc.$18
Across 53 payments — averaging $33,704 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.1M
- Eisai Inc.$489K
- Sanofi$101K
- E.r. Squibb & Sons, L.L.C.$70K
What the payments were for
- Food & beverage$94892%
- Education$858%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $407 |
| Exelixis Inc. | 29 | $393 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| AstraZeneca | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$255
How this compares
$1,033 in reported general payments places this provider in the 25th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 52 | $619,732 |
| ErleadaApalutamide | 47 | $604,647 |
| WeliregBelzutifan | 12 | $355,047 |
| InlytaAxitinib | 20 | $298,837 |
| NubeqaDarolutamide | 23 | $280,381 |
| OrgovyxRelugolix | 46 | $118,680 |
| Abiraterone Acetate | 109 | $106,377 |
| LynparzaOlaparib | 12 | $89,310 |
| OxycontinOxycodone Hcl | 12 | $13,220 |
| EliquisApixaban | 15 | $8,427 |
| Testosterone | 28 | $8,306 |
| Morphine Sulfate ErMorphine Sulfate | 53 | $1,067 |
| Morphine Sulfate | 34 | $939 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $859 |
| Methylphenidate Hcl | 44 | $780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $407 | $604,64747 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $18 | $118,68046 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $127 | $106,377109 claims |
| AstraZenecaLynparza | $20 | $89,31012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.